• The Company has a portfolio of over 150 products across 15 therapeutic areas with annual sales of over Rs. 2,000 crores.
  • Its top brands include Prevenar 13, Lyrica, Corex – DX, Dolonex, Enbrel, Becosules, Gelusil and Folvite among others


Company Overview

Pfizer Limited (NSE: PFIZER) was listed on the Indian stock exchange in 1966. Today, the company has over one lac shareholders in India. With annual sales of over Rs. 2,000 crores, it is the fourth largest multinational pharmaceutical company in India. The Company has a portfolio of over 150 products across 15 therapeutic areas. 1

Its top brands include Prevenar 13, Lyrica, Corex – DX, Dolonex, Enbrel, Becosules, Gelusil and Folvite among others. In addition to its commercial operations, Pfizer Limited also operates a state-of-the-art, award-winning manufacturing facility in Goa that produces more than a billion tablets annually.

The Company employs 2,631 colleagues, and is committed to providing therapies to prevent and treat some of the most critical diseases that impact public health in India today.


Plant Location

  • Verna, Goa
  • Thane Belapur Road, Navi Mumbai

Industry Overview

According to the Indian Economic Survey 2021, the domestic pharmaceutical market is expected to grow three times in the next decade to US$ 42 billion in 2021 and US$ 65 billion by 2024 and may reach ~US$ 120-130 billion by 2030. 2

The Union Budget 2021 puts a spotlight on health and well-being. Doubling up healthcare spending and allocating a sizable outlay for developing capacities of primary, secondary and tertiary healthcare systems and promoting new and existing institutions to concentrate on emerging diseases over the next 6 years, is a welcome move. The focus is now on overall well-being of the people including preventive and curative health with a larger emphasis on immunization. Allocating Rs 35,000 crore for COVID-19 vaccine and the assurance that any additional spending required would be provided for vaccination, is a welcome step. However, much needs to be done to improve national healthcare spending as a percentage of GDP.

Indian Pharmaceutical Industry

Market Overview

The Indian pharma market (IPM) grew at 4.3% over the April 2020 - March 2021 period, with a turnover of  Rs 1,56,797 Crore. The growth was primarily driven by price, which contributed 4.3% to the total, followed by new products at 3.6% and volume at -3.6%. Multinational companies hold about 20% share in the market and have grown at 2.6%.

Therapeutic Growth

Cardiac has overtaken anti-infectives to emerge as the top therapy. Antivirals have registered highest growth of 161% due to pandemic. The acute care segment is growing at a meager 2% due to low patient volume during the pandemic. Anti-infective, being the most impacted, declined by 12%. Within the acute therapeutic areas, vitamins, minerals & supplements (VMS) was least impacted. Chronic segment has also suffered due to the pandemic as growth slipped to 8.4% (Mar’21 MAT) from 11.7% (Mar’20 MAT). Both cardiac and cardiovascular and neuroscience (CNS) therapies posted double-digit growths.

COVID-19 Impact on Pharmaceutical Industry

IPM grew faster in March 2021 due to the base effect of lockdown beginning March 25, 2020. IPM growth declined to 4.3% in 2021 as compared to 10.5% growth last year. Loss in potential sales is estimated at approximately Rs 8,000 Crore.

The impact was higher as the lockdown period overlapped with monsoon season which typically are growth drivers for acute therapeutic areas. With limited face-to-face detailing, new launches were either delayed or saw lower uptake but are now picking up. Vitamins has shown strong recovery driven by consumer awareness and their role in immunity building for COVID-19. The respiratory therapeutic area has shown lower growth levels. A research indicates lockdown linked drop in asthma attacks mainly due to lower levels of air pollution, fewer cold and flu infections. Limited access to healthcare professionals in Tier 1 Cities due to stricter lockdown, reverse migration, lower inter-district travel for medicine purchase and increased focus on rural markets are potential drivers for rural growth. Going forward, health systems needs to be mindful of increasing co-morbidities/ new diagnosis in COVID-19 recovered patients.


Business Overview

The company collectively addresses 15 therapy areas with a portfolio of over 150 products that include therapeutics and vaccines.


Vaccine: The company’s Vaccine business focuses on a pneumococcal conjugate vaccine - Prevenar 13. This vaccine provides broad coverage against the most prevalent 13 serotypes of streptococcus pneumoniae. Prevenar 13 is now ranked 16th in the Indian Pharma Industry (March 2021). Prevenar 13 is truly the only vaccine for all age groups, as the Drugs Controller General of India in May 2021 has granted approval for 18-49 years age group in addition to the pediatric, adolescent and 50 plus age group.

The company continues to enjoy a leadership position in the pneumococcal vaccines market with a share of 55.4%. It is committed towards creating awareness, education and make vaccines available so that more individuals can be protected against devastating pneumococcal infections.

Inflammation and Immunology

The Inflammation and Immunology vertical makes available medicines to patients suffering from chronic diseases related to immune system like Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Internal Bowel Diseases. These advance therapies include drugs made from protein-cytokine, and oral therapies that manage inflammation and pain. The goal of this team is to transform the management of chronic inflammatory diseases, many of which are not well managed by existing treatment options that provide only symptomatic relief.

Internal Medicine

In 2019-20, the company’s Internal Medicine (IM) team framed a new mission for the next five years and developed a strategic roadmap – “To deliver sustainable, market-beating growth through differentiated go-to-market strategies (GTM)”. The key shift in GTM was to create two distinct market segments: Core market, focused on specialists in the urban geographies and Multiplier market, focused on general/family physicians in the extra-urban rural geographies.

During the year under review, this shift in GTM enabled the company to significantly maximize its presence in specialties like cardiologists, gynecologists, chest physicians, orthopedics etc. in the core geographies and increased reach and penetration in the rural and extra-urban geographies, leading to consistent market beating growth for key brands. The company also deployed innovative digital channels to improve trade engagement (retail, semi-stockist, stockist) across core and multiplier markets and ensure availability of key medicines for the patients, especially during lockdown.

Respiratory Portfolio

The company has presence in the Respiratory portfolio with Cough, Oral Corticosteroids and Smoking Cessation therapies. The flagship brand Corex Dx has maintained leadership position in the dry cough Respiratory Portfolio Market with 18.1% value market share. One of the major initiatives taken during the year was ‘cough the right way’ –a campaign that aimed to create awareness and educate patients on good practices to be followed to avoid spread of infections. As part of future growth strategy, the company continues to focus on building brands in the productive cough segment with line extensions of Corex LS and Corex LS Junior.

During the year, there has been continued focus on the smoking cessation drug Champix with launch of #BreakTheStick campaign. The campaign was initiated by the company in November 2020 with the aim to create an ecosystem to support smokers looking to quit smoking, while also enabling more primary care physicians to address smoking cessation successfully. A detailed omnichannel programme aided outreach to over 1,00,000 consumers, with 14,000 engaging on the for a deeper understanding of the therapy, and over 330 smokers going through with an actual online consultation. The HCP engagement arm of the programme, designed for primary care physicians and chest physicians, empowered over 2500 doctors through more than 25 Key Opinion Leader (KOL) advisory and certification programs.

Vitamins Portfolio

The company’s flagship brand Becosules continues to lead and shape the B-complex vitamins market with growth of 32%. With a legacy of more than 60 years, the brand is still growing faster than the market with an Evolution Index (EI) of 103, which has resulted in moving its market share to 75.1%. Continuous focus on expanding the prescriber base, increasing consumer demand and innovative channel initiatives have been the key pillars to strengthen brand’s leadership.

With Becosules getting the over the counter (OTC) brand status coupled with the new GTM model helped the company to expand its retail reach. The company also drove aggressive retail engagement and connect at approximately 50,000 chemist outlets and build consumer awareness to help them Boost Immunity with Becosules.

Neuroscience and Cardiovascular

The company’s Neuroscience portfolio represents multiple brands that are leaders in their respective segments. Pacitane (Trihexyphenidyl) leads in its therapeutic category with 68% market share with 13% growth over last year. Ativan (Lorazepam) is the second largest anxiolytic brand in the Benzodiazepine Tranquilizer market growing at 14.6%.

The Cardiovascular (CV) team operates in the antihypertensive segment with its brands Minipress XL and Targit Range. Minipress, the leading brand in the market, for uncontrolled hypertension has maintained its market share at 43.9% with growth of 8% and EI of 101. The company continued its engagement activities in the area of uncontrolled hypertension through medico-marketing initiatives with physicians, nephrologists and cardiologists.


Eliquis® (Apixaban) a Factor Xa Inhibitor Anticoagulant is a leading oral Anticoagulant, predominantly prescribed by cardiologists, cardio like physicians and orthopedic surgeons. Eliquis is the leader in the Novel Oral Anti-Coagulants (NOAC) Market, with an EI of 125 and it grew by 69% over last year same period as per MAT Mar 2021.

During the year under review, the team has bought in extraordinary reach and penetration for the brand through the new go-to-market strategies. As per this new structure, Eliquis is now promoted by two teams under one leadership, allowing for increased reach amongst consulting physicians and orthopedic surgeons while sharpening focus and coverage amongst cardiologists. This co-marketing strategy has also helped maximize geographic penetration beyond metro and tier 1 cities which enables the company to improve lives of more patients across the country than ever before.

Women’s Healthcare

The company’s portfolio in Women’s Healthcare comprises many of the segment’s iconic brands, supporting important life-stages like pregnancy, menopause, reproductive health including contraception. Brands like Folvite, Autrin, Premarin and Ovral L continue to maintain their leadership position in the represented market and the consolidated portfolio continues to grow faster than the market average. Shift in go-to-market strategies and enhanced focus on gynecologists accelerated the prescription growth and now three brands in the portfolio – Folvite, Autrin and Folvite MB feature amongst the top 100 IPM brands prescribed by gynecologists.

Gastric portfolio

The company has presence in gastroenterology segment with brands like Neksium, Gelusil and Mucaine. The focus of its Esomeprazole Proton Pump Inhibitor (PPI) - Neksium, has been on delivering excellence by driving strong in-clinic focus at key specialties including gastroenterologists and orthopedicians. The company launched Gastroesophageal Reflux Disease (GERD) Clinic, Pfizer’s first ever annual initiative to reach more than 10,000 HCPs and drive GERD awareness. The company has intensified focus on nursing homes and small hospitals that have helped sustain momentum. Neksium D, launched in 2019, continues to build growth for the brand and has been positioned to drive differentiation by targeting patients with symptoms related to Refractory GERD.

Pain and inflammation portfolio

The company has a pronounced presence in the pain and inflammation category with brands Dolonex (Piroxicam) and Wysolone (Prednisolone). Both are legacy brands with more than 40 years of presence in India and are leaders in their respective categories, having impacted lives of more than 10 million patients in the Country. Dolonex DT and Wysolone both have a strong EI of 101 and 112 respectively indicating that they are growing faster than the market. The company has continued its engagement activities in osteoarthritis (OA) and low back pain (LBP) through medico-marketing initiatives with orthopedicians and physicians on treating OA and LBP.

The portfolio expanded in December 2020, with the introduction of Dolonex E (Etoricoxib) for the treatment of osteoarthritis. The company plans to further expand the portfolio to provide a range of solutions for management of osteoarthritis.


The company’s Hospitals business unit focuses on institutions such as hospitals and nursing homes with an advanced anti-infectives and sterile injectables portfolio.

Pfizer’s original breakthrough innovative and patented drug Zavicefta 2gm/0.5gm (ceftazidime-avibactam) has recorded an exponential growth driven by increased uptake across more number of hospitals. This novel drug is indicated for the management of hospital-acquired pneumonia including ventilator-associated pneumonia (HAP/VAP), complicated intra-abdominal infection (cIAI) and complicated urinary infection (cUTI) in adults. The emergence and spread of carbapenemase-producing pathogens are a concern and has highlighted the urgent need for new antimicrobial agents.


Financial Highlights

financial results for the quarter and year ended March 31, 2021.

Pfizer Limited announced its Audited results for the quarter and year ended March 31, 2021. 3


Revenue from operations for the quarter ended March 31, 2021 stood at ₹535 crore as compared to ₹502 crore in the same period last year, a growth of 6.5%.

Revenue from operations for the year ended March 31, 2021 is ₹2,239 crore as compared to ₹2,152 crore in the same period last year, showing a 4% growth.

In India, the COVID-19 pandemic continued to develop rapidly into 2021, with a significant rise in the number of cases. The current year sales, primarily for Hospitals and Vaccines businesses, have been impacted due to the pandemic.

The Company has monitored the impact of COVID-19 on all aspects of its business. The management has exercised due care, in concluding significant accounting judgements and estimates, recoverability of receivables, assessment for impairment of goodwill, intangible assets, inventory based on the information available as on date, while preparing the financial results as of and for the year ended March 31, 2021.

While business-critical functions continued to be fully operational to ensure there are no interruptions in the delivery of its medicines to the hospitals and patients, rest of the colleagues worked from home. Several measures have been put in place for communications, technology and productivity improvements to help employees cope with this change.

Consumer Healthcare business

During the current quarter, the Company completed the wind down activities for its Consumer Healthcare business consisting of two brands – Anacin and Anne French. The compensation of ₹27.5 crore derived based on the fair value of Pfizer Consumer Healthcare Products as determined by the independent valuers along with the incremental wind down cost of ₹11.6 crore will be received by the Company.

Profits before other income and tax

Profit from operations (before other income and tax) for the quarter ended March 31, 2021 registered a growth of 23% to ₹98 crore as against ₹80 crore in the same period last year.

Profit from operations (before other income and tax) for the year ended March 31, 2021 registered a growth of 28% to ₹603 crore as against ₹469 crore in the same period last year.

Net profit for the year

Net Profit after tax for the quarter ended March 31, 2021 is ₹100 crore as against ₹103 crore in the same period last year

Net Profit after tax for the year ended March 31, 2021 is ₹497 crore as against ₹509 crore in the same period last year

Quarter and Year ending March 2020 had Prior year tax reversals ₹44 crore, thereby resulting in the lower net profit during the period / year when compared with same period last year


The Board of Directors of the Company has recommended a normal dividend of Rs 30/- per equity share of Rs 10/- each (300%) and a special dividend of Rs 5/- per equity share of Rs 10/- each (50%), aggregating to total dividend of Rs 35/- per equity share of Rs 10/- each (350%) for the year ended March 31, 2021.


  1. ^
  2. ^
  3. ^
Created by Asif Farooqui on 2021/08/09 20:28

Become a Contributor

If you follow a company closely and would like to share your knowledge, we would love your contributions. Register Now and start editing!

Tag Cloud

  1. AU:DTL
  2. AU:PNC
  3. AU:SSR
  4. Bangladesh
  5. BD:ACI
  10. BD:GP
  14. BD:RBBL
  16. BD:ROBI
  20. CA:ABX
  21. CA:AC
  22. CA:AEM
  23. CA:AFI
  24. CA:AGI
  25. CA:BAM.A
  26. CA:BCE
  27. CA:BLDP
  28. CA:BMO
  29. CA:BNS
  30. CA:BTO
  31. CA:CCO
  32. CA:CM
  33. CA:CNQ
  34. CA:CNR.TO
  35. CA:CP
  36. CA:CSU
  37. CA:CU
  38. CA:CVE
  39. CA:EMA
  40. CA:ENB
  41. CA:FFH
  42. CA:FM
  43. CA:FSV
  44. CA:FTS
  45. CA:GFL
  46. CA:GIB
  47. CA:GWO
  48. CA:IFC
  49. CA:IMO
  50. CA:K
  51. CA:LULU
  52. CA:MFC
  53. CA:MG
  54. CA:MRU
  55. CA:MX
  56. CA:NA
  57. CA:NG
  58. CA:NTR
  59. CA:OTEX
  60. CA:POW
  61. CA:PVG
  62. CA:QSR
  63. CA:RBA
  64. CA:RCI.A
  65. CA:RY
  66. CA:SHOP
  67. CA:SJR.B
  68. CA:SLF
  69. CA:SSRM
  70. CA:SU
  71. CA:T
  72. CA:TA
  73. CA:TARD
  74. CA:TD
  75. CA:TECK
  76. CA:TFII
  77. CA:TRI
  78. CA:TRP
  79. CA:WEED
  80. CA:X
  81. CA:YRI
  82. Canada
  83. CH:ALSN
  84. CH:NESN
  85. CIPLA
  86. DE:TIMA
  87. EU:CCAP
  88. EU:HHFA
  89. FR:CEN
  90. FR:HCO
  91. GB:AAL
  92. GB:ABDN
  93. GB:ABF
  94. GB:ADM
  95. GB:AHT
  96. GB:ANTO
  97. GB:AUTO
  98. GB:AUY
  99. GB:AV
  100. GB:AVST
  101. GB:AVV
  102. GB:AZN
  103. GB:BA
  104. GB:BARC
  105. GB:BATS
  106. GB:BDEV
  107. GB:BHP
  108. GB:BME
  109. GB:BP
  110. GB:CCH
  111. GB:CPG
  112. GB:CTO
  113. GB:DARK
  114. GB:DGE
  115. GB:FERG
  116. GB:GLEN
  117. GB:HL
  118. GB:HSBA
  119. GB:IHG
  120. GB:III
  121. GB:IMB
  122. GB:INCH
  123. GB:NWG
  124. GB:NXR
  125. GB:OCDO
  126. GB:REL
  127. GB:RKT
  128. GB:SGE
  129. GB:SGRO
  130. GB:SKG
  131. GB:SMIN
  132. GB:SN
  133. GB:STAN
  134. GB:ULVR
  135. Great Britain
  136. HK:0995
  137. HK:1052
  138. HK:107
  139. HK:189
  140. HK:548
  141. HK:819
  142. HK:995
  143. IN:3MINDIA
  146. IN:CIPLA
  150. IN:IDEA
  152. IN:LICI
  153. IN:LUPIN
  154. IN:LUPINE
  155. IN:MFSL
  156. IN:MOFSL
  161. IN:NBCC
  163. IN:NIACL
  164. IN:NMDC
  166. IN:OFSS
  168. IN:PAYTM
  169. IN:PEL
  171. IN:PFIZER
  172. IN:PGHH
  174. IN:PIIND
  175. IN:PNB
  178. IN:QUESS
  180. IN:RELAXO
  181. IN:SAIL
  182. IN:SANOFI
  185. IN:SRF
  188. IN:TECHM
  189. IN:TITAN
  192. IN:TRENT
  194. IN:UBL
  197. IN:UPL
  198. IN:VBL
  200. IN:ZEEL
  201. India
  202. Ireland
  203. JP:1070
  204. JP:2654
  205. JP:4220
  206. JP:4734
  207. JP:6916
  208. SG:BCY
  209. SG:F13
  210. UK:IHG
  211. US:AABA
  212. US:AAOI
  213. US:AAPL
  214. US:AAUKF
  215. US:ABEO
  216. US:ABUS
  217. US:ACAD
  218. US:ACAN
  219. US:ACBFF
  220. US:ACDVF
  221. US:ACHN
  222. US:ACIA
  223. US:ACRX
  224. US:ADAP
  225. US:ADMP
  226. US:ADMS
  227. US:ADXS
  228. US:AEM
  229. US:AEZS
  230. US:AFMD
  231. US:AGEN
  232. US:AGI
  233. US:AGRX
  234. US:AGTK
  235. US:AKAO
  236. US:ALDR
  237. US:ALIM
  238. US:ALQA
  239. US:AMC
  240. US:AMD
  241. US:AMDA
  242. US:AMIGF
  243. US:AMMJ
  244. US:AMN
  245. US:AMPE
  246. US:AMRN
  247. US:AMRS
  248. US:AMZN
  249. US:ANCUF
  250. US:ANFGF
  251. US:ANLDF
  252. US:ANTH
  253. US:ANY
  254. US:APHQF
  255. US:AQMS
  256. US:AQSZF
  257. US:ARDX
  258. US:ARGS
  259. US:ARLZ
  260. US:ARNA
  261. US:ARRY
  262. US:ARWR
  263. US:ASBFF
  264. US:ASHTF
  265. US:ATDRY
  266. US:ATHX
  267. US:ATNM
  268. US:ATOS
  269. US:ATRS
  270. US:AUPH
  271. US:AUY
  272. US:AVASF
  273. US:AVEO
  274. US:AVEVF
  275. US:AVGR
  276. US:AVIR
  277. US:AVP
  278. US:AVVIY
  279. US:AVXL
  280. US:AXON
  281. US:AXSM
  282. US:AZN
  283. US:BABA
  284. US:BAC
  285. US:BAESF
  286. US:BAM
  287. US:BBRY
  288. US:BCE
  289. US:BCOR
  290. US:BCS
  291. US:BHC
  292. US:BHP
  293. US:BIOA
  294. US:BIOC
  295. US:BLCM
  296. US:BLDP
  297. US:BLEVF
  298. US:BLOZF
  299. US:BLPH
  300. US:BLRX
  301. US:BMO
  302. US:BMRPF
  303. US:BNS
  304. US:BP
  305. US:BPMX
  306. US:BSTG
  307. US:BTDPF
  308. US:BTE
  309. US:BTG
  310. US:BTI
  311. US:BW
  312. US:BZUN
  313. US:CALA
  314. US:CANN
  315. US:CAPR
  316. US:CARA
  317. US:CASC
  318. US:CATB
  319. US:CBDS
  320. US:CCJ
  321. US:CEI
  322. US:CERC
  323. US:CERU
  324. US:CHK
  325. US:CIE
  326. US:CLDX
  327. US:CLF
  328. US:CLOV
  329. US:CLSN
  330. US:CLVS
  331. US:CM
  332. US:CMPGF
  333. US:CNAB
  334. US:CNAT
  335. US:CNBX
  336. US:CNI
  337. US:CNQ
  338. US:CNSWF
  339. US:CORT
  340. US:CP
  341. US:CPRX
  342. US:CRBP
  343. US:CRIS
  344. US:CRMD
  345. US:CTRV
  346. US:CU
  347. US:CUR
  348. US:CVE
  349. US:CVSI
  350. US:CYCC
  351. US:CYTR
  352. US:CYTX
  353. US:DCTH
  354. US:DEPO
  355. US:DGEAF
  356. US:DMPI
  357. US:DRKTF
  358. US:DRYS
  359. US:DVAX
  360. US:DXTR
  361. US:DYLLF
  362. US:EARS
  363. US:ECYT
  364. US:EDIT
  365. US:EGLT
  366. US:EKSO
  367. US:ELVT
  368. US:ENB
  369. US:ENDP
  370. US:ENRT
  371. US:ETRM
  372. US:EVC
  373. US:EXEL
  374. US:FATE
  375. US:FB
  376. US:FERG
  377. US:FINL
  378. US:FIT
  379. US:FLXN
  380. US:FOLD
  381. US:FQVLF
  382. US:FRFHF
  383. US:FSV
  384. US:FTR
  385. US:FTS
  386. US:FVE
  387. US:FWDG
  388. US:GALE
  389. US:GALT
  390. US:GBHPF
  391. US:GBT
  392. US:GERN
  393. US:GFL
  394. US:GIB
  395. US:GILD
  396. US:GLDFF
  397. US:GLEN
  398. US:GLYC
  399. US:GME
  400. US:GNCA
  401. US:GNMX
  402. US:GOLD
  403. US:GPRO
  404. US:GSAT
  405. US:GVXXF
  406. US:GWLIFU
  407. US:HLTH
  408. US:HMNY
  409. US:HRGLF
  410. US:HRTX
  411. US:HSBA
  412. US:HTGM
  413. US:HTZ
  414. US:HUSA
  415. US:ICPT
  416. US:IDRA
  417. US:IDXG
  418. US:IFCZF
  419. US:IHG
  420. US:IMBBF
  421. US:IMGN
  422. US:IMMU
  423. US:IMNP
  424. US:IMO
  425. US:IMUC
  426. US:INFI
  427. US:INPX
  428. US:INSM
  429. US:INVA
  430. US:ITEK
  431. US:IVITF
  432. US:JD
  433. US:JOBS
  434. US:JVA
  435. US:KAYS
  436. US:KEM
  437. US:KERX
  438. US:KGC
  439. US:KTOS
  440. US:KTOV
  441. US:LKM
  442. US:LODE
  443. US:LPCN
  444. US:LULU
  445. US:LXRP
  446. US:MACK
  447. US:MARA
  448. US:MBOT
  449. US:MBRX
  450. US:MDCL
  451. US:MDCO
  452. US:MEET
  453. US:MEIP
  454. US:MEOH
  455. US:MFC
  456. US:MGA
  457. US:MGWFF
  458. US:MNKD
  459. US:MOMO
  460. US:MQPXF
  461. US:MRNS
  462. US:MRTX
  463. US:MSFT
  464. US:MTRAFU
  465. US:MU
  466. US:MVIS
  467. US:MZOR
  468. US:NAK
  469. US:NBEV
  470. US:NBRV
  471. US:NEOS
  472. US:NG
  473. US:NH
  474. US:NLNK
  475. US:NMUS
  476. US:NTIOF
  477. US:NTNX
  478. US:NTR
  479. US:NVAX
  480. US:NVCN
  481. US:NVDA
  482. US:NVRO
  483. US:NWBO
  484. US:NWG
  485. US:NXTTF
  486. US:NYMX
  487. US:OCDGF
  488. US:OCLR
  489. US:OCUL
  490. US:OGRMF
  491. US:OMER
  492. US:ONCS
  493. US:ONTX
  494. US:ONVO
  495. US:OPGN
  496. US:OPHT
  497. US:OPK
  498. US:OPTT
  499. US:OTEX
  500. US:OTIC
  501. US:P
  502. US:PANXF
  503. US:PBYI
  504. US:PETS
  505. US:PETX
  506. US:PGNX
  507. US:PHOT
  508. US:PIRS
  509. US:PLSE
  510. US:PLUG
  511. US:PLX
  512. US:PRTO
  513. US:PSDV
  514. US:PTI
  515. US:PTN
  516. US:PTX
  517. US:PUFXF
  518. US:PULM
  519. US:PVG
  520. US:QRSRF
  521. US:QSR
  522. US:RAD
  523. US:RBA
  524. US:RBGPF
  525. US:RCI
  526. US:RCKT
  527. US:RDHL
  528. US:RDUS
  529. US:RELX
  530. US:REPH
  531. US:RGLS
  532. US:RIGL
  533. US:RNN
  534. US:RNVA
  535. US:ROX
  536. US:RSSFF
  537. US:RTTR
  538. US:RY
  539. US:SCYX
  540. US:SDRL
  541. US:SEGXF
  542. US:SENS
  543. US:SESN
  544. US:SGBY
  545. US:SGGEF
  546. US:SGMO
  547. US:SGYP
  548. US:SHOP
  549. US:SJR
  550. US:SKLN
  551. US:SLF
  552. US:SLFPF
  553. US:SMFTF
  554. US:SMGKF
  555. US:SNAP
  556. US:SNN
  557. US:SPHS
  558. US:SPLIF
  559. US:SPRWF
  560. US:SQ
  561. US:SRNA
  562. US:SRNE
  563. US:SRRA
  564. US:SSRM
  565. US:STLY
  566. US:STML
  567. US:STMP
  568. US:STRRF
  569. US:SU
  570. US:SWN
  571. US:SYN
  572. US:TAC
  573. US:TBQBF
  574. US:TD
  575. US:TECK
  576. US:TENX
  577. US:TEVA
  578. US:TFII
  579. US:TGOPF
  580. US:TGTX
  581. US:THCBF
  582. US:TK
  583. US:TMXXF
  584. US:TNDM
  585. US:TOP
  586. US:TRI
  587. US:TROV
  588. US:TRP
  589. US:TRTC
  590. US:TRVN
  591. US:TRXC
  592. US:TSG
  593. US:TSLA
  594. US:TTM
  595. US:TTNP
  596. US:TTNQY
  597. US:TU
  598. US:TVTY
  599. US:TWTR
  600. US:TXMD
  601. US:UBQU
  602. US:UNXL
  603. US:VAPE
  604. US:VBLT
  605. US:VCEL
  606. US:VDQSF
  607. US:VPCO
  608. US:VSTM
  609. US:WIT
  610. US:WLDFF
  611. US:WLL
  612. US:WMIH
  613. US:WMT
  614. US:XGTI
  615. US:XON
  616. US:XTNT
  617. US:XXII
  618. US:ZGNX
  619. US:ZSAN
  620. US:ZYNE
This site is funded and maintained by